IL13 and urethra adenocarcinoma: Consensus was achieved on several statements related to the indication for biologics in patients with UAD, such as the use of anti-IL-4/IL-13 or anti-IgE regardless of the presence of allergy (M: 8), although the level of agreement was lower among allergists.